Central Sleep Apnea

Use sleep testing that records airflow, respiratory effort, oxygen saturation, and sleep state when possible to establish whether recurrent events occur with absent or insufficient ventilatory effort, the defining physiologic feature of CSA. In-laboratory polysomnography provides sleep staging and simultaneous respiratory measurements; ambulatory or unattended testing and overnight oximetry can support screening, but abbreviated recordings may miss obstructive events or incompletely characterize mixed disease. jacc+2jaccSleep Apnea and Cardiovascular Disease: An American Heart Association/American College of Cardiology Foundation Scientific Statement From the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing In Collaboration With the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health)ScienceDirectCentral Sleep Apnea - an overviewScienceDirectCentral Sleep Apnea Syndrome - an overview

At the interpretation visit, classify the dominant pattern rather than treating the apnea-hypopnea index alone. Cheyne-Stokes respiration, awake periodic breathing, hyperventilation with hypocapnia, and periodic breathing during exercise point toward a heart-failure-associated high-loop-gain phenotype; persistent obstructive events require a different airway-directed approach. jacc+1jaccSleep Apnea and Cardiovascular Disease: An American Heart Association/American College of Cardiology Foundation Scientific Statement From the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing In Collaboration With the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health)Oxford AcademicCentral sleep apnea: pathophysiologic classification

Obtain a focused etiologic history before prescribing a ventilatory device: chronic heart failure, opioid exposure, high-altitude exposure, and apparently idiopathic disease are recognized settings for central respiratory events. Medication-induced CSA is a distinct clinical entity; identify chronic opioid use specifically and reassess whether the exposure can be reduced, discontinued, or replaced in coordination with the prescribing clinician. Oxford Academic+1Oxford AcademicMedication-induced central sleep apnea - Oxford AcademicCochranePharmacological treatment for central sleep apnoea in ...

CSA occurs in approximately 35% of patients with heart failure across ejection-fraction categories, and estimates in HFrEF range from approximately 30% to 50%. In a patient with known heart failure and sleep-related symptoms or periodic breathing, establish the sleep phenotype and reassess cardiac status rather than attributing symptoms solely to congestion, insomnia, or obstructive apnea. jacc+1jaccPhrenic Nerve Stimulation for the Treatment of Central Sleep Apnea | JACC: Heart FailureOxford AcademicCurrent and future developments in the field of central sleep ...

Optimize guideline-based heart-failure management as the first therapeutic step for heart-failure-associated CSA. The AHA/ACCF statement lists optimization of heart-failure treatment, positive airway pressure, and supplemental oxygen among management options; the choice of any sleep-directed intervention should follow confirmation of central predominance and LVEF assessment. jaccjaccSleep Apnea and Cardiovascular Disease: An American Heart Association/American College of Cardiology Foundation Scientific Statement From the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing In Collaboration With the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health)

Treat awake or upright Cheyne-Stokes respiration as a marker of a higher-risk physiologic phenotype rather than a standalone target for empiric ventilatory escalation. In one heart-failure cohort assessed with brief supine and upright polygraphy, 14% had CSR that persisted upright, and upright CSR independently predicted 8-year mortality; this association supports careful heart-failure assessment and risk-oriented follow-up, not unproven treatment of the breathing pattern itself. jaccjaccUpright Cheyne-Stokes Respiration in Heart Failure: Look But Don’t Touch∗

Positive airway pressure options for CSA include CPAP, bilevel PAP, and ASV, while supplemental oxygen is another noninvasive option in heart-failure-associated CSA. CPAP and bilevel PAP have been reported to be more effective than no treatment for CSA management in heart failure and opioid use, but modality choice should be individualized to the central phenotype, coexisting obstruction, tolerance, and cardiac safety profile. jacc+1jaccSleep Apnea and Cardiovascular Disease: An American Heart Association/American College of Cardiology Foundation Scientific Statement From the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing In Collaboration With the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health)PubMedCentral Sleep Apnea - StatPearls - NCBI Bookshelf

ASV delivers servo-controlled inspiratory pressure support on top of expiratory positive airway pressure and can markedly suppress central events. That physiologic efficacy must not be used as a surrogate for safety in HFrEF: in SERVE-HF, adults with LVEF 45% or less, NYHA class II-IV symptoms, AHI at least 15 events/hour, and predominantly central events had increased all-cause and cardiovascular mortality with ASV despite improved AHI. NEJM+2NEJMAdaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure | New England Journal of MedicinePubMedAdaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure - PubMedACCTreatment of Sleep-Disordered Breathing With Predominant Central Sleep Apnea by Adaptive Servo-Ventilation in Patients With Heart Failure - American College of Cardiology

For persistent CSA in an appropriate candidate, transvenous unilateral phrenic nerve stimulation is an implantable alternative intended to restore a more physiologic nocturnal breathing pattern. Prospective data support feasibility and reduction in CSA severity, and subsequent reports describe improved sleep quality and quality of life regardless of prior PAP treatment or heart-failure status. Evaluate the procedural tradeoff against noninvasive options, ongoing device follow-up, and the patient’s symptom burden. jacc+2jaccPhrenic Nerve Stimulation for the Treatment of Central Sleep Apnea | JACC: Heart FailurePubMedCentral Sleep Apnea - StatPearls - NCBI BookshelfScienceDirectMultidimensional phenotyping to distinguish among central ...

For opioid-associated CSA, make medication reconciliation a treatment intervention rather than merely a documentation task. Determine the opioid agent, total daily exposure, timing relative to sleep, coadministration of other sedating drugs, and whether pain, palliative, or addiction-treatment goals permit dose reduction or substitution. Chronic opioid use is an established setting for CSA, and persistent sleep-related respiratory symptoms should be reassessed after the exposure strategy changes. Oxford Academic+1Oxford AcademicMedication-induced central sleep apnea - Oxford AcademicCochranePharmacological treatment for central sleep apnoea in ...

For CSA occurring outside heart failure or opioid exposure, identify high-altitude exposure and consider whether central events persist after removal of a reversible trigger. Idiopathic CSA remains a diagnostic category only after clinically relevant secondary conditions have been considered; treatment decisions should be individualized because some CSA cases resolve spontaneously. ScienceDirect+1ScienceDirectCentral Sleep Apnea - an overviewCochranePharmacological treatment for central sleep apnoea in ...

Pharmacologic approaches, including acetazolamide, have been studied for CSA, including in heart failure, but the cited evidence base does not provide a dose or a routine first-line regimen. Do not extrapolate a drug dose from unrelated indications; use pharmacotherapy only with a defined phenotype, a specific therapeutic target, and planned follow-up of respiratory response and adverse effects. Cochrane+1CochranePharmacological treatment for central sleep apnoea in ...CochranePharmacological treatment for central sleep apnoea in adults

At follow-up, document treatment adherence, residual respiratory-event burden, nocturnal oxygenation, sleep disruption, and daytime sleepiness. A therapy that reduces AHI but fails to improve symptoms, sleep quality, or clinically meaningful outcomes should trigger reassessment of event classification, cardiac status, exposure to opioids or sedatives, and treatment tolerability. SERVE-HF demonstrates why normalized respiratory indices cannot substitute for safety and outcome assessment. NEJM+2NEJMAdaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure | New England Journal of MedicinePubMedAdaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure - PubMedACCTreatment of Sleep-Disordered Breathing With Predominant Central Sleep Apnea by Adaptive Servo-Ventilation in Patients With Heart Failure - American College of Cardiology

Escalate to a sleep specialist and cardiology collaboration when CSA occurs with symptomatic heart failure, when CSR is observed awake or upright, when an implantable phrenic nerve stimulation system is being considered, or when mixed central-obstructive findings leave the optimal PAP strategy uncertain. Sleep testing should be reviewed at the signal level when the diagnosis determines whether ASV is excluded by LVEF. jacc+3jaccUpright Cheyne-Stokes Respiration in Heart Failure: Look But Don’t Touch∗jaccSleep Apnea and Cardiovascular Disease: An American Heart Association/American College of Cardiology Foundation Scientific Statement From the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing In Collaboration With the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health)PubMedAdaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure - PubMedACCTreatment of Sleep-Disordered Breathing With Predominant Central Sleep Apnea by Adaptive Servo-Ventilation in Patients With Heart Failure - American College of Cardiology

Counsel patients with heart failure explicitly that ASV is not a benign escalation for central events in the LVEF 45% or less population. In SERVE-HF, the primary composite outcome occurred in 54.1% of the ASV group and 50.8% of controls, while all-cause and cardiovascular mortality increased with ASV; avoid reassuring patients based solely on improved device-reported AHI. NEJM+1NEJMAdaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure | New England Journal of MedicinePubMedAdaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure - PubMed